At present, these drugs are used in clinical practice or ongoing clinical trials on EGFR mutations, ALK rearrangements, ROS1 rearrangements, BRAF V600E mutation, MET exon 14 splice site, and KRAS G12c mutation‐positive NSCLC treatment.1, 2, 3, 4, 5, 6, 7, 8, 9, 10. This evidence concerns the gene BRAF and non-small cell lung carcinoma.